中臺灣地區高尿酸血症個體之代謝症候群盛行率

135

ၡāāࢋ

2004 3065

18 81 ( 635 2430 )

( Odds ratio ) 9 mg/dL

5 mg/dL 5.64 7.62

ᙯᔣෟĈ੼Ԍᅕҕা ( Hyperuricemia )

΃ᔁা࣏ཏ ( Metabolic syndrome )

઼઼࡚छᓙ׽ዔିֈࢍ൪јˠڼᒚ໤݋ௐˬѨಡӘ ( NCEP/ATP III )

͔֏

੼ԌᅕҕাдᓜԖ˯̙֭͌֍Ăॲፂ͛ᚥ˯

ಡӘĂҘ઼͞छ̝஽Җதࡗࠎ 8.7-35.1%

Ă҃д ᄂ៉۞௚ࢍአߤ݋ࠎ 17.3-25.8%

Ąధкࡁտព ϯ੼Ԍᅕࣃࠎ΃ᔁা࣏ཏ ( metabolic syndrome ) ၹ јࢋ৵̝˘

Ăͷᄃ۲ࡡ

Ăཬ෈Ꭴ̙࡝া

Ă੼

ҕ਌া

Ă੼ҕᑅ

ѣ඾ព඾۞࠹ᙯᓑĄ 2001 ѐ࡚

઼൴ܑ"઼छᓙ׽ዔିֈࢍ൪"( NCEP ) ̝јˠڼᒚ

໤݋ௐˬѨಡӘ ( Adult Treatment Panel III report, ATP III )Ăቁᄮ΃ᔁা࣏ཏࠎ͕ҕგ়ঽ̝кࢦኑ ᗔПᐍЯ̄ĂૻአᑕצՀкᓜԖᗁर۞ڦຍ

Ą ࡁտពϯᖣϤ΃ᔁা࣏ཏ۞ᎡᏴ̈́ѝഇڼᒚĂΞ ഴ͕͌ҕგ়ঽ۞൴Ϡ

ĄҭߏĂд੼Ԍᅕҕা

۞࣎វ̚Ă̙Т඀ޘ۞Ԍᅕࣃߏӎົᇆᜩ΃ᔁা

࣏ཏ̝஽ҖதĂҌϫ݈ࠎͤĂإ൑ѩᙷ̝ώ˿ّ

ಡӘĄЯѩĂԧࣇဘྏෞҤ̙Тඈ৺Ԍᅕࣃ̝࣎

វĂ׎΃ᔁা࣏ཏ۞஽ҖதĂ֭ଣ੅̙Т۞ّҾ ѐ᛬д఺ֱ௡Ҿ̚Ă၆ٺ΃ᔁা࣏ཏ̝ᇆᜩĄ

Մफ़̈́͞ڱ

ώࡁտ၆෪פҋҘ̮ 2004 ѐ˘͡Ҍ˩˟͡

ม Ă ̚ ొ ߙ ᗁ ጯ ̚ ͕ ۞ ࣶ ̍ Ϡ ͟ វ ᑭ ྤ फ़ В 3065 Ҝ ( 635 ҜշّĂ 2430 Ҝّ̃ )ĄЧ჌ҕ୵

۞Ϡ̼޽ᇾ̈́ٙѣ֗វᑭߤ̝តᇴೀͼ࠰ٺТ˘

ॡมԆјĄҕᑅ۞ณീߏд٩ҕ݈Ăଳӱݻֹ֭

ϡҋજ̼۞ҕᑅࢍീณĄ֗វኳณ޽ᇴͽវࢦ ( kg ) ੵͽ֗੼π͞ ( m

) ࢍზĄཕಛീณͽϩ͎

ᖒ࿅ཕొĂአፋ੼ޘֹਕ఼࿅νΠ׌઎བ੻˯ቡ Ҍ҈੻˭ቡ̝̚มᕇĂჯ޺ϒ૱ײӛĂٺФঈඕ ՁॡĂณפཕಛĄ

Ϡ̼ᑭീͽ۩ཛҌ͌ˣ̈ॡޢĂѝ˯٩ҕᑭ

ീĄ΃ᔁা࣏ཏ۞ؠཌྷߏણ໰ֲ߷ᇾ໤Ă࣒Լҋ Ҙ̮ 2001 ѐ NCEP/ATP III ۞ؠཌྷĂ႕֖˭Е୧ І ( ӣ ) ˬีͽ˯۰Ĉշّཕಛ̂ٺ 90 ̶̳ẵ

ّ̂ٺ 80 ̶̳Ăˬᅕϟڵ਌̂ٺ 150 mg/dL Ăշ

ّ੼૜ޘ਌కϨᓙ׽ዔҲٺ 40 mg/dL ẵّҲ ٺ 50 mg/dL Ăҕᑅ̂ٺඈٺ 130/85 mmHg Ă۩

ཛҕᎤ̂ٺඈٺ 100 mg/dL Ą

ϓཏវ۞Чีૄώྤफ़ͽπӮࣃ Ų ᇾ໤म ೡࢗĄ΃ᔁা࣏ཏ۞஽ҖதĂֶࡁտ၆෪۞Ԍᅕ ࣃ੼Ҳ̶ј ( 1 ) ̈ٺ 5 mg/dL ( 2 ) 5-6.9 mg/dL ( 3 ) 7-8.9 mg/dL ( 4 ) ̂ٺٕඈٺ 9 mg/dL ඈ 4 ௡ࢍზĄ ͽទᏭਫ਼ᕩ̶ژෞҤĂЧ௡࠹၆ٺԌᅕࣃ̈ٺ 5 mg/dL ఺௡̝࠹၆Пᐍͧࣃ ( Odds Ratio, OR ) ̈́ ७ϒѐ᛬ăّҾޢ۞࠹၆ПᐍͧࣃĂ̈́७ϒѐ

᛬ăّҾă҉ᅕքࣃăវࢦ̈́Ϩҕ஧௟ࡪࢍᇴޢ

۞࠹၆ПᐍͧࣃĄѩγĂԧࣇ˵ࢍზ̙Т۞΃ᔁ

া࣏ཏ௡јЯ̄ᇴณд̙ТԌᅕࣃ௡Ҿ྆۞Ѻ̶

ͧĂ̙̈́Тඈ৺۞ѐ᛬ăّҾдЧԌᅕࣃ௡Ҿ۞

΃ᔁা࣏ཏ஽ҖதĄ

ඕڍ

ώࡁտπӮѐ᛬ࠎ 32.9 ໐Ă 20.7% ࠎշّĂ πӮ֗វኳณ޽ᇴ 22.5 kg/m

ĂπӮԌᅕࣃ 5.37 Ų 1.45 mg/dL ( ܑ˘ )Ąඕڍពϯ΃ᔁা࣏ཏ۞஽

ҖதĂᐌԌᅕࣃ۞ᆧΐ҃Ӕனព඾ّ۞ᆧΐĄд

̃Ϡ୉ཏ̚ĂԌᅕࣃ̂ٺ 5 mg/dL ۞Ч௡ᄃԌᅕ ࣃ̈ٺ 5 mg/dL ఺௡۞΃ᔁা࣏ཏ࠹၆Пᐍͧࣃ

ֶԔ̶Ҿࠎ 3.36 Ă 14.57 ̈́ 36.15 ( P < 0.001 )Ăѩ ᙯܼд७ϒкีតᇴ ( Β߁ѐ᛬ăវࢦĂ҉ᅕք ࣃ̈́Ϩҕ஧ࢍᇴ ) ޢ̪ѣ࠹Т۞ඕڍ ( ܑ˟̝˘ )

ܑ˘Ĉ Demographic data of the study population ( n = 3065 )

Mean Ų SD Range

Gender ( Male ) 20.7%

Age ( year-old ) 32.9 Ų 8.9 18 - 81 BW ( kg ) 58.94 Ų 11.96 32.4 - 142.1 BMI ( kg/m

) 22.451 Ų 3.678 14.10 - 45.36

WC ( cm ) 76.1 Ų 10.0 54 - 128

SBP ( mm-Hg ) 115.7 Ų 14.5 73 - 197

DBP ( mm-Hg ) 79.1 Ų 10.3 40 - 131

FPG ( mg/dL ) 89.6 Ų 13.5 61 - 325

HDL-C ( mg/dL ) 62.2 Ų 14.3 28 - 118 Triglyceride ( mg/dL ) 86.4 Ų 64.3 21 - 1176 LDL-C ( mg/dL ) 108.3 Ų 29.7 26 - 260 WBC No. ( /ɢ L ) 6048.8 Ų 1594.4 2400 - 18600 Creatinine ( mg/dL ) 0.85 Ų 0.17 0.5 - 2.0 Uric acid ( mg/dL ) 5.37 Ų 1.45 1.3 - 13.1

ܑ˟̝˘Ĉ Prevalence of the Metabolic Syndrome in Women According to Serum Uric Acid Levels Uric Acid Levels (mg/dL)

N = 2430 < 5 ( n = 1330 ) 5 - 6.9 ( n = 981 ) 7 - 8.9 ( n = 112 ) Ÿ 9 ( n = 7 ) Prevalence, % (95% CI) 2.0 ( 1.2 - 2.8 ) 6.5 ( 5.0 - 8.0 ) 23.2 ( 15.4 - 31.0 ) 42.9 ( 6.2 - 79.6 ) Unadjusted OR (95% CI) 1.0 3.36 (2.13-5.32)Ő 14.57 (8.15-26.05)Ő 36.15 (7.71-169.42)Ő Age-adjusted OR (95% CI) 1.0 3.13 (1.97-4.96)Ő 12.06 (6.65-21.87)Ő 36.59 (7.69-174.07)Ő Mutivariate OR

(95% CI) 1.0 1.78 (1.07-2.96)Ő 4.54 (2.29-9.00)Ő 7.62 (1.06-55.07)Őā OR = odds ratio; CI = confidence interval

*

Adjust for age, creatinine level, body weight and white cell count

Ő p < 0.05

ǕԌᅕࣃ̂ٺ 5 mg/dL ۞ˬ௡Ă׎࠹၆Пᐍͧࣃ Чࠎ̈ٺ 5 mg/dL ఺௡۞ 1.78 ă 4.54 ̈́ 7.62 ࢺĄ ҭ д շ Ϡ ୉ ཏ ̚ Ă Ϊ ѣ Ԍ ᅕ ࣃ ̂ ٺ ٕ ඈ ٺ 9 mg/dL ۞఺௡Ă׎΃ᔁা࣏ཏ࠹၆ПᐍͧࣃࠎԌ ᅕࣃ̈ٺ 5 mg/dL ఺௡۞ 5.64 ࢺͷ׍௚ࢍຍཌྷ ( ܑ˟̝˟ )Ą΃ᔁা࣏ཏ௡јЯ̄۞ᇴณĂдԌ ᅕࣃ̈ٺ 5 mg/dL ఺௡ĂҌк΍ன 4 ࣎Я̄Ăҭ ѣ 3 ٕ 4 ࣎Я̄۞ͧத̙֭੼ĂЧࠎ 0 . 2 % ̈́ 1.9% ć΍ன 3 ă 4 ă 5 ࣎Я̄۞Ѻ̶ͧĂᐌ඾Ԍᅕ ࣃ۞ᆧΐ҃ᆧΐĂ՟ѣЇң΃ᔁা࣏ཏ௡јЯ̄

۞Ѻ̶ͧĂ݋ᐌ඾Ԍᅕࣃ۞˯̿҃ഴ͌ ( ဦ˘ )Ą Ч௡Ҿֶ̙ТّҾ̶ژΞ൴னĂ̙ኢշ̃ϠĂ༊

Ԍᅕࣃດ੼ॡĂ΃ᔁা࣏ཏ஽Җதಶ෸ດ੼Ăҭ Т௡Ҿ۞շ̃Ă׎஽Җத݋՟ѣमҾĄЧ௡Ҿֶ

ϓཏវ۞ѐ᛬үα̶Ҝᇴ̶௡Ă֭७ϒّҾăវ ࢦĂ҉ᅕքࣃ̈́Ϩҕ஧ࢍᇴඈЯ৵ޢĂ൴னੵ˞

Ԍᅕࣃ̈ٺ 5 mg/dL ۞఺௡γĂ΃ᔁা࣏ཏ۞஽

Җத࠰ᐌѐ᛬ᆧΐ҃ᆧΐ ( ဦ˟ )Ą

੅ኢ

ώࡁտෞҤԌᅕࣃ੼Ҳᄃ΃ᔁা࣏ཏ۞࠹ᙯ

ّĂ൴னԌᅕࣃດ੼۞௡ҾĂ΃ᔁা࣏ཏ۞஽Җ தດ੼ĂӈֹԯᇆᜩԌᅕࣃ੼Ҳ۞кีЯ৵Еˢ

҂ᇋ֭ΐͽ७ϒޢĂ̪൒ѣТᇹ۞ᔌ๕Ąѩᙷඕ ڍдߙֱ͛ᚥ˵൴னĂ΃ᔁা࣏ཏ۞஽Җதᄃҕ

୻ԌᅕࣃӔϒ࠹ᙯّ

Ąҕ୻Ԍᅕࣃ̿੼˵૱֍

ٺ੼ˬᅕϟڵ⟯

ă੼ҕᑅ

̈́੼ҕᎤ

۞࣎

វĂ҃఺ֱЯ̄ϒߏ΃ᔁা࣏ཏ۞௡јࢋ৵Ąҕ

̚࿅੼۞਍फ৵ົᆧΐඪ̈გ၆ٺทᗓ̄۞Гӛ ќĂซ҃ܡᘣඪ᝙ଵ΍Ԍᅕ۞ਕ˧

Ăౄјҕ୻

Ԍᅕࣃ۞˯̿Ăٙͽ༊ҕ୻̚਍फ৵ࣃ෸੼ॡĂ ԌᅕࣃಶΞਕ෸੼ĄϤٺ΃ᔁা࣏ཏ˵ߏ˘჌੼

ဦ˘Ĉ Percentage of metabolic syndrome compo- nents at variable serum uric acid levels MetS = Metabolic syndrome.

ܑ˟̝˟Ĉ Prevalence of the Metabolic Syndrome in Men According to Serum Uric Acid Levels Uric Acid Levels (mg/dL)

N = 635 < 5 ( n = 29 ) 5 - 6.9 ( n = 303 ) 7 - 8.9 ( n = 239 ) Ÿ 9 ( n = 64 ) Prevalence, % (95% CI) 6.9 ( 0 - 16.1 ) 13.9 ( 10 - 17.8 ) 20.9 ( 15.7 - 26.1 ) 39.1 ( 27.1 - 51.1 ) Unadjusted OR (95% CI) 1.0 2.17 (0.50-9.47) 3.57 (0.82-15.52) 8.65 (1.89-39.62)Ő Age-adjusted OR (95% CI) 1.0 2.15 (0.49-9.50) 4.08 (0.93-17.99) 10.65 (2.28-49.70)Ő Mutivariate OR

(95% CI) 1.0 2.59 (0.51-13.13) 3.24 (0.65-16.27) 5.64 (1.05-130.26)Őā OR = odds ratio; CI = confidence interval

*

Adjust for age, creatinine level, body weight and white cell count Ő p < 0.05

ဦ˟Ĉ Prevalence of metabolic syndrome according to serum uric acid levels stratified by age group.

Age was divided by quartile, with ascending or- der from Q1 to Q4 (The range of age in Q1 ŷ 26, Q2: 27 - 30, Q3: 31 - 37, Q4 Ÿ 38 ). Trend of p value in each group by uric acid level are <

0.05 (except the group with uric acid level < 5

mg/dL).

਍फ৵ҕা۞ېၗ

ĂТॡҡᐌѣ੼Ԍᅕҕা۞

ଐڶಶ̙֖ࠎ؈˞ĄԌᅕࣃ࿅੼Ξਕጱ࡭ҕგ̰

ϩ௟ࡪ۞Αਕצຫ

Ăมତౄј੼ҕᑅ۞൴ϠĄ ΩγĂԌᅕࣃ࿅੼۞࣎វ˵૱Ъ׀ѣ੼ˬᅕϟڵ

⟯ҕাĂᔵ൒ࣧЯ̪൒̙ځቁĂҭΞ൴னҕ୻ˬ ᅕ ϟ ڵ ⟯ ۞ ፧ ޘ ᄃ Ԍ ᅕ ࣃ ۞ ੼ Ҳ Ӕ ன ϒ ࠹ ᙯ

ّ

Ąტ˯ٙࢗĂ੼Ԍᅕҕা૱૱ҡᐌ඾΃ᔁ

া࣏ཏ۞Ч࣎௡јЯ̄Ăٙͽ༊Ԍᅕࣃ෸੼ॡĂ

΃ᔁা࣏ཏ۞஽ҖதߏΞਕᆧΐ۞Ą

΃ᔁা࣏ཏ΃ܑ̰᝙ݭ۲ࡡă੼ҕᑅăҕ

਌ள૱̈́਍फ৵ܡԩጱ࡭۞ཬ෈Ꭴ̙࡝া۞ཏ

௡Ăιߏ൴णјજਔඓᇹർ̼ă݄ېજਔ͕᝙

ঽ̈́ཝୟ๫۞ВТঽந፟ᖼ

Ąώࡁտ൴னĂ ጐგԌᅕࣃ఍ٺϒ૱ቑಛ̰Ă΃ᔁা࣏ཏ۞஽

Җதٕ௡јЯ̄۞ᇴณĂ̪ߏᐌԌᅕࣃ̿੼҃

ᆧΐĄѩ჌΃ᔁা࣏ཏ௡јЯ̄΍ன۞ͧதĂ ᐌԌᅕࣃ˯̿҃ѣព඾ّ۞ᆧΐ۞ࡁտ˵അѣ

ಡጱ

Ăҭдڌ͞ˠ۞͛ᚥಡӘ݋̙к֍Ąጐ

გ˘ֱࡁտពϯĂ੼Ԍᅕҕা׶͕ҕგ়ঽ۞

ᙯܼĂд७ϒ׎ιПᐍЯ̄ޢ̙֖֭ͽឰԌᅕ ၹј͕ҕგ়ঽ۞፾ϲПᐍЯ̄

Ă Framingham ࡁտ˵Ә෦ԧࣇԌᅕࣃ֭ܧ݄ېજਔ͕᝙ঽ۞፾

ϲ࠹ᙯПᐍЯ̄

Ăҭ Tae ඈˠ൴னĂ੼Ԍᅕࣃ ᄃ੼ҕᑅĂ਍फ৵ܡԩѣ፾ϲ࠹ᙯĂࠤҌԌᅕࣃ

̪఍ٺϒ૱ቑಛॡĂ˵Ξ៍၅ז΃ᔁা࣏ཏ۞Ч

ีЯ̄ᐌԌᅕࣃ̿੼҃ᆧΐ

Ą Barbara ඈˠ൴ னĂᐌ඾΃ᔁা࣏ཏ௡јЊЯ̄΍னͧத۞ᆧ ΐĂ 5 ѐޢ͕ҕგ়ঽ̈́ᎤԌঽ۞൴Ϡ፟ົ૟ᐌ

̝ᆧΐ

ĄॲፂώࡁտĂԌᅕࣃ̂ٺٕඈٺ 9 mg/dL ఺௡дշ̙̃Т۞୉ཏ㝯Ă΍ன΃ᔁা࣏

ཏ۞࠹၆ПᐍͧࣃЧࠎ̈ٺ 5 mg/dL ֤௡۞ 5.64

̈́ 7.62 ࢺĂຍק඾੼Ԍᅕࣃ۞΍னĂ͍׎ߏԌ ᅕࣃள૱੼ॡĂ׀х΃ᔁা࣏ཏ۞፟ົᐌ̝̂

ᆧĂጾѣ௡јЯ̄۞ᇴณ˵೩੼ĄϤѩଯኢĂ

੼Ԍᅕҕা۞࣎९׎૟ֽ̝͕ҕგ়ঽ̈́ᎤԌ ঽ۞൴Ϡ፟ົ૟੼ٺ˘ਠϒ૱ˠĄЯѩĂᓜԖ ᗁर၆ٺ׍ѣள૱Ԍᅕࣃ۞࣎९ᑕ೩੼ᛋᛇĂ υื൴ଧߏӎѣ΃ᔁা࣏ཏЧีЯ̄۞хдĂ

֭ͷ̈́ѝ᎕ໂ̬ˢ࿰֨̈́ڼᒚĄ

ֶّҾ̶௡ࢍზĂ΃ᔁা࣏ཏ۞஽ҖதĂ̙

ኢّҾ࠰ᐌԌᅕࣃ۞ᆧΐ҃ព඾ّᆧΐĂ҃дТ

ඈ৺۞Ԍᅕࣃ௡Ҿ̚Ăշّ̃۞஽Җத࠹༊Ą̃

ّෲႬᄋົឰඪ̈გ၆ٺԌᅕ۞Гӛќഴ͌Ăᇆ ᜩԌᅕࣃ۞੼Ҳ

ć࠹ͅ۞ĂշّෲႬᄋ۞፧

ޘ݋ᄃԌᅕࣃ۞੼Ҳѣϒ࠹ᙯّ

ĄٙͽдТᇹ

۞Ϡந୧І˭Ăշّ۞Ԍᅕࣃᑕྍ̂ٺّ̃ĄϤ ѩଯኢĂдТඈ৺۞Ԍᅕࣃ̶௡˭Ă΃ᔁা࣏ཏ Ч௡јЯ̄дّ̃΍ன۞ͧதΞਕົ̂ٺշّĂ

˵ಶߏᄲĂ΃ᔁা࣏ཏ۞஽Җதّ̃ᑕྍкٺշ

ّ

Ąҭώࡁտ۞ᇹώĂдТ˘Ԍᅕࣃ۞௡Ҿ

྆Ăշّ۞វࢦ̂ٺّ̃Ăጱ࡭΃ᔁা࣏ཏ۞ͧ

த˯̿Ă߇७ϒវࢦ۞Я৵ޢĂշّ̃۞஽Җத

՟ѣमளĄѐ᛬ߏՙؠ΃ᔁা࣏ཏ۞˘࣎Я৵̝

˘Ăѐࡔ෸̂Ă׎஽Җத˵෸੼

Ąώࡁտֶ

ѐ᛬̶௡ࢍზ̶ژޢĂੵ˞Ԍᅕࣃ̈ٺ 5 mg/dL

఺௡γĂ΃ᔁা࣏ཏ۞஽Җதᐌѐ᛬̝ᆧΐ҃ᆧ ΐĂ׎ΞਕࣧЯࠎĈԌᅕࣃ̈ٺ 5 mg/dL ఺௡۞

΃ᔁা࣏ཏ஽ҖதྵҲ ( 2.1% )ĂౄјГֶѐ᛬̶

௡ॡĂЧ̶௡࣎९ᇴ͉͌҃՟ѣ௚ࢍጯ˯۞ຍ ཌྷĄ

ώࡁտ۞ٙѣྤफ़ֽҋᗁੰࣶ̍Ϡ͟វᑭྤ

फ़Ă၆ٺ࣎ˠ۞Ϡ߿ݭၗă࿅ΝঽΫ̈́ߏӎڇϡ ᘽۏඈЯ৵Ă֭՟ѣΐͽෞҤĂ߇׎ඕڍΞਕѣ

ٙᄱमĄ׎ѨĂᇹώ࠰ֽҋ̚ొߙ˘ᗁጯ͕̚Ă Ξਕхдפᇹ˯۞ઐमĂߏӎਕᑕϡٺБᄂ៉୉

ཏΞਕᅮГซ˘ՎෞҤĄΩγĂώࡁտࠎ˘ፖ߱

ё۞ࡁտĂΪߏ៍၅זԌᅕࣃ੼Ҳᄃ΃ᔁা࣏ཏ

۞஽Җதѣ׎࠹ᙯّĂ൑ڱۢ྽׎ЯڍᙯܼĂߏ ӎԌᅕࣃᆧΐົۡତౄј΃ᔁা࣏ཏ۞΍னᆧΐ ߏ൑ڱଯኢ۞Ą

ඕኢ

ώࡁտࠎଣ੅Ԍᅕࣃ੼Ҳᄃ΃ᔁা࣏ཏ۞ᙯ

ܼĈԌᅕࣃ෸੼ĂЪ׀ѣ΃ᔁা࣏ཏ۞፟ົᐌ̝

̂ᆧĂ׎Ч௡јЯ̄΍ன۞ͧத˵෸੼ĂӈֹԌ ᅕࣃ఍ٺϒ૱ቑಛ̰˵ѣ࠹Т۞ன෪ĄдТ˘Ԍ ᅕࣃඈ৺˭Ăѐࡔྵ̂ॡ˵Ξ៍၅ז΃ᔁা࣏ཏ

۞Ξਕّ̿੼Ąѩඕڍ೩ᏹᓜԖᗁरĂ੼ޘڦຍ Ԍᅕࣃ׎ࡦޢΞਕ۞ຍཌྷĂ̈́ѝ᎕ໂ̬ˢ࿰֨̈́

ڼᒚ͕ҕგ়ঽ۞൴ϠĄҌٺࢋԆБ˞ྋԌᅕࣃ

੼Ҳᄃ΃ᔁা࣏ཏПᐍّ۞ЯڍᙯܼĂᅮГซ˘

Վү݈ᖀّ۞ࡁտ̶ژĄ

ણ҂͛ᚥ

1.Conen D, Wietlisbach V, Bovet P, et al. Prevalence of hyper- uricemia and relation of serum uric acid with cardiovascular risk factors in a developing country. BMC Public Health. 2004; 25:

4-9.

2.Chou P, Soong LN. Community-based epidermiologic study on hyperuricemia in Pu-Li, Taiwan. J Formos Med Assoc 1993; 92:

597-602.

3.Lin KC, Lin HY, Chou P. Community based epidermiologic study on hyperuricemia and gout in Kin-Hu, Kinmen. J Rheumatol 2000; 27: 1045-50.

4.Onat A, Uyarel H, Hergen G, et al. Serum uric acid is a deter- minant of metabolic syndrome in a population-based study. Am J Hypertens 2006; 19: 1055-62.

5.Bonora E, Targher G, Zenere MB, et al. Relationship of uric acid concentration to cardiovascular risk factors in young men. Role of obesity and central fat distribution. The Verona Young Men Atherosclerosis Risk Factors Study. Int Obes Relat Metab Disord 1996; 20: 975-80.

6.Lee J, Sparrow D, Vokonas PS, Landsberg L, Weiss ST. Uric acid and coronary heart disease risk: evidence for a role of uric acid in the obesity-insulin resistance syndrome. The Normative Aging Study. Am J Epidemiol 1995; 142: 288-94.

7.Emmerson B. Hyperlipidemia in hyperuricemia and gout. Ann Rheum Dis 1998; 57: 509-10.

8.Taniguchi Y, Hayashi T, Tsumura K, Endo G, Fujii S, Okada K.

Serum uric acid and the risk for hypertension and type 2 dia- betes in Japanese men: The Osaka Health Survey. J Hypertens 2001; 19: 1209-15.

9.Third report of the National Cholesterol Education Program (N- CEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III).

Final report. Circulation 2002; 106: 3143-421.

10.Jermendy G, Hetyesi K, Biro L, et al. Prevalence of the metabol- ic syndrome in hypertensive and/or obese subjects. Diabet Med 2004; 21: 805-6.

11.Choi HK, Ford ES. Prevalence of the metabolic syndrome in in- dividuals with hyperuricemia. Am J Med 2007; 120: 442-7.

12.Conen D, Wietlisbach V, Bovet P, et al. Prevalence of hyper- uricemia and relation of serum uric acid with cardiovascular risk factors in a developing country. BMC Public Health 2004; 4: 1- 9.

13.Nakanishi N, Suzuki K, Kawashimo H, Nakamura K, Tatara K.

Serum uric acid: correlation with biological, clinical and be- havioral factors in Japanese men. J Epidemiol 1999; 9: 99-106.

14.Bonora E, Targher G, Zenere MB, et al. Relationship of uric acid concentration to cardiovascular risk factors in young men: role of obesity and central fat distribution. The Verona Young Men Atherosclerosis Risk Factors Study. Int J Obes Relat Metab Disord 1996; 20: 975-80.

15.Selby JV, Friedman GD, Quesenberry CP Jr. Precursors of es- sential hypertension: pulmonary function, heart rate, uric acid,

serum cholesterol, and other serum chemistries. Am J Epidemiol 1990; 131: 1017-27.

16.Golembiewska E, Ciechanowski K, Safranow K, Kedzierska K, Kabat-Koperska J. Renal handling of uric acid in patients with type 1 diabetes in relation to glycemic control. Arch Med Res 2005; 36: 32-5.

17.Facchini F, Chen YD, Hollenbeck CB, Reaven GM. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA 1991; 266: 3008-11.

18.Reaven GM. Role of insulin resistance in human disease.

Diabetes 1988; 37: 1595-607.

19.Kanellis J, Kang DH. Uric acid as a mediator of endothelial dys- function, inflammation, and vascular disease. Semin Nephrol 2005; 25: 39-42.

20.Klein BE, Klein R, Lee KE. Components of the metabolic syn- drome and risk of cardiovascular disease and diabetes in beaver dam. Diabetes Care 2002; 25: 1790-4.

21.Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syn- drome and total and cardiovascular disease mortality in middle- aged men. JAMA 2002; 288: 2709-16.

22.McNeill AM, Rosamond WD, Girman CJ, et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care 2005; 28: 385-90.

23.Solymoss BC, Bourassa MG, Campeau L, et al. Effect of in- creasing metabolic syndrome score on atherosclerotic risk pro- file and coronary artery disease angiographic severity. Am J Cardiol 2004; 93: 159-64.

24.Desai MY, Santos RD, Dalta D, at al. Relation of serum uric acid with metabolic risk factors in asymptomatic middle-aged Brazilian men. Am J cardiol 2005; 95: 865-8.

25.Iribarren C, Folsom AR, Eckfeldt JH, McGovern PG, Neito FJ.

Correltaes of uric acid and its association with asymptomatic carotid atherosclerosis: the ARIC Study. Atherosclerosis Risk in Communities. Ann Epidemiol 1996; 6: 331-40.

26.Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular diaease and death: The Framingham Heart Study. Ann Intern Med 1999; 131: 7-13.

27.Moriarity JT, Folsom AR, Iribarren C, Nieto FJ, Rosamond WD.

Serum uric acid and risk of coronary heart disease:

Atherosclerosis Risk in Communities (ARIC) Study. Ann Epidemiol 2000; 10: 136-43.

28.Yoo TW, Sung KC, Shin HS, et al. Relationship between serun uric acid concentration and insulin resistance and metabolic syn- drome. Circ J 2005; 69: 928-33.

29.Sumino H, Ichikawa S, Kanda T, et al. Reduction of serum uric acid by hormone replacement therapy in postmenopausal wom- en with hyperuricemia. Lancet 1999; 354: 650.

30.Wingrove CS, Walton C, Stevenson JC. The effect of menopause on serum uric acid levels in non-obese healthy women.

Metabolism 1998; 47: 435-8.

31.Denzer C, Muche R, Mayer H, Heinze E, Debatin KM, Wabitsch

M. Serum uric acid levels in obese children and adolescents:

linkage to testosterone levels and pre-metabolic syndrome. J Pediatr Endocrino Metab 2003; 16: 1225-32.

32.Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syn- drome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-9.

33.Kuzuya M, Ando F, Iguchi A, Shimokata H. Age-specific change

of prevalence of metabolic syndrome: longitudinal observation of large Japanese cohort. Atherosclerosis 2007; 191: 305-12.

34.Hildrum B, Mykletun A, Hole T, Midthjell K, Dahl AA. Age- specific prevalence of the metabolic syndrome defined by the International Diabetes Federation and the National Cholesterol Education Program: the Norwegian HUNT 2 study. BMC Public Health 2007; 7: 220.

Prevalence of the Metabolic Syndrome in

Individuals with Hyperuricemia in Central Taiwan

Dong-Hwa Tsai and Shi-Dou Lin

The occurrence of cardiovascular disease can be reduced by the screening and early treatment of metabol- ic syndrome. However, little information existed about whether different graded levels of uric acid in individuals with hyperuricemia will affect the prevalence of metabolic syndrome in Taiwan. The potential application of hy- peruricemia was also studied little. To investigate the association between different uric acid levels and preva- lence of metabolic syndrome, a total of 3065 subjects of all hospital staff, aged 18 to 81 years (635 males, 2430 females), who received health examination from Jan. 2004 to Dec. 2004 were enrolled in our study. The study showed that the prevalence of metabolic syndrome increased significantly across successive grade of serum uric acid concentrations, also the odds ratio (ORs) for the association between increasing levels of serum uric acid and the metabolic syndrome. Those who had serum uric acid concentrations Ÿ 9 mg/dL had a 5.18-fold increased in risk of metabolic syndrome, as compaired with those with concentrations Ŵ 5 mg/dL. Percentage of the more metabolic syndrome components increased as the serum uric acid concentrations increased. The prevalence of metabolic syndrome in each subgroup of the same uric acid level persisted in increasing across successive quar- tiles of age. This study indicate that high serum uric acid confers increased risk or prevalence of metabolic syn- drome even for those whose uric acid levels are in the normal range but with higher age. In clinical practice, since high serum uric acid is associated with higher prevalence of metabolic syndrome, we must think hyper- uricemia as an important potential marker for cardiovascular disease. ( J Intern Med Taiwan 2008; 19: 325-330 )

Division of Endocrinology and Metabolism, Department of Internal Medicine,

Changhua Christian Hospital, Changhua, Taiwan